AndrÃ" M Ilbawi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4670381/publications.pdf Version: 2024-02-01



Δνισά" Μ.Ιιβλυμ

#	Article	IF	CITATIONS
1	Global challenges and policy solutions in breast cancer control. Cancer Treatment Reviews, 2022, 104, 102339.	3.4	74
2	Essential medicines list in national cancer control plans: a secondary analysis from a global study. Lancet Oncology, The, 2022, 23, e144-154.	5.1	9
3	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncology, The, 2022, 23, e251-e312.	5.1	94
4	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Global Oncology, 2022, , .	0.8	2
5	The Global Landscape of Treatment Standards for Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1143-1155.	3.0	13
6	Impact of Strategies for Mitigating Delays and Disruptions in Cancer Care Due to COVID-19: Systematic Review. JCO Global Oncology, 2021, 7, 342-352.	0.8	17
7	Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review. JCO Global Oncology, 2021, 7, 311-323.	0.8	286
8	The World Cancer Declaration: time to consolidate wins and work towards 2025. Lancet Oncology, The, 2021, 22, 296-298.	5.1	7
9	The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncology, The, 2021, 22, 578-581.	5.1	104
10	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncology, The, 2021, 22, 1367-1377.	5.1	69
11	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
12	Childhood cancer control during the COVID-19 pandemic. Lancet Oncology, The, 2021, 22, 1348-1350.	5.1	2
13	National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. Lancet Oncology, The, 2021, 22, 1632-1642.	5.1	84
14	An ethical imperative: Safety and specialization as nursing priorities of WHO Global Initiative for Childhood Cancer. Pediatric Blood and Cancer, 2020, 67, e28143.	0.8	19
15	Cancer care for refugees: time to invest in people and systems. Lancet Oncology, The, 2020, 21, 604-605.	5.1	10
16	Strengthening the global nursing workforce for childhood cancer. Lancet Oncology, The, 2020, 21, 1550-1552.	5.1	1
17	How to reduce the impact of cervical cancer worldwide: Gaps and priority areas identified through the essential cancer and primary care packages: An analysis of effective interventions. Cancer, 2020, 126, 4697-4705.	2.0	6
18	Working Together to Build a Better Future for Children With Cancer in Africa. JCO Global Oncology, 2020, 6, 1076-1078.	0.8	13

AndrÃ" M Ilbawi

#	Article	IF	CITATIONS
19	Analysis of Mammography Screening Schedules under Varying Resource Constraints for Planning Breast Cancer Control Programs in Low- and Middle-Income Countries: A Mathematical Study. Medical Decision Making, 2020, 40, 364-378.	1.2	2
20	Interventions Addressing Barriers to Delayed Cancer Diagnosis in Low―and Middleâ€Income Countries: A Systematic Review. Oncologist, 2020, 25, e1382-e1395.	1.9	16
21	Opportunities to improve cancer control and progress towards universal health coverage in Commonwealth nations. Lancet Oncology, The, 2020, 21, 876-879.	5.1	1
22	Areca Nut and Betel Quid Control Interventions: Halting the Epidemic. Substance Use and Misuse, 2020, 55, 1552-1559.	0.7	7
23	First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open, 2020, 5, e000587.	2.0	43
24	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, The, 2020, 395, 591-603.	6.3	321
25	Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports. ESMO Open, 2020, 5, e000878.	2.0	5
26	Identifying Breast Cancer Care Quality Measures for a Cancer Facility in Rural Sub-Saharan Africa: Results of a Systematic Literature Review and Modified Delphi Process. JCO Global Oncology, 2020, 6, 1446-1454.	0.8	2
27	Delays and Barriers to Cancer Care in Low- and Middle-Income Countries: A Systematic Review. Oncologist, 2019, 24, e1371-e1380.	1.9	85
28	Core elements of national cancer control plans: a tool to support plan development and review. Lancet Oncology, The, 2019, 20, e645-e652.	5.1	33
29	Maximising clinical benefit with adequate patient management beyond the second line in mCRC. ESMO Open, 2019, 4, e000495.	2.0	14
30	Cancer Control at the District Hospital Level in Sub-Saharan Africa: An Educational and Resource Needs Assessment of General Practitioners. Journal of Global Oncology, 2019, 5, 1-8.	0.5	5
31	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. ESMO Open, 2019, 4, e000538.	2.0	7
32	Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies. JAMA Network Open, 2019, 2, e186875.	2.8	58
33	Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open, 2018, 3, e000285.	2.0	169
34	World Health Organization List of Priority Medical Devices for Cancer Management to Promote Universal Coverage. Clinics in Laboratory Medicine, 2018, 38, 151-160.	0.7	15
35	A Two-Step Markov Processes Approach for Parameterization of Cancer State-Transition Models for Low- and Middle-Income Countries. Medical Decision Making, 2018, 38, 520-530.	1.2	13
36	Knowledge Summaries for Comprehensive Breast Cancer Control. Journal of Global Oncology, 2018, 4, 1-7.	0.5	12

AndrÃ" M Ilbawi

#	Article	IF	CITATIONS
37	Effect on longevity of one-third reduction in premature mortality from non-communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target. The Lancet Global Health, 2018, 6, e1288-e1296.	2.9	90
38	Cost-effective interventions for breast cancer, cervical cancer, and colorectal cancer: new results from WHO-CHOICE. Cost Effectiveness and Resource Allocation, 2018, 16, 38.	0.6	27
39	Defining priority medical devices for cancer management: a WHO initiative. Lancet Oncology, The, 2018, 19, e709-e719.	5.1	15
40	National cancer control plans: a global analysis. Lancet Oncology, The, 2018, 19, e546-e555.	5.1	109
41	Advancing access and equity: the vision of a new generation in cancer control. Lancet Oncology, The, 2017, 18, 172-175.	5.1	7
42	Priorities and funding for global cancer surgery research. Journal of Surgical Oncology, 2017, 115, 513-516.	0.8	3
43	Perioperative therapies – Enhancing the impact of cancer surgery with repurposed drugs. European Journal of Surgical Oncology, 2017, 43, 1985-1988.	0.5	13
44	Reply: Global Cancer Consortiums: Moving from Consensus to Practice. Annals of Surgical Oncology, 2017, 24, 550-550.	0.7	5
45	Global Cancer Consortiums: Moving from Consensus to Practice. Annals of Surgical Oncology, 2015, 22, 719-727.	0.7	10
46	Breast Cancer in Low and Middle Income Countries (LMICs): A Shifting Tide in Global Health. Breast Journal, 2015, 21, 111-118.	0.4	68
47	Wide Local Excision of Perianal Mucinous Adenocarcinoma. Journal of Clinical Oncology, 2015, 33, e16-e18.	0.8	5
48	Cancer in global health: How do prevention and early detection strategies relate?. Science Translational Medicine, 2015, 7, 278cm1.	5.8	36
49	Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncology, The, 2015, 16, 1193-1224.	5.1	442
50	Surgical Services for Cancer Care. , 2015, , 223-238.		7
51	Obstacles to Surgical Services in a Rural Cameroonian District Hospital. World Journal of Surgery, 2013, 37, 1208-1215.	0.8	23
52	Morphologic study of the ascending aorta and aortic arch in hypoplastic left hearts: Surgical implications. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 99-105.	0.4	16